Background & Aims: Recently, spatial-temporal/metabolic 21 mathematical models have been established that allow the sim-22
ulation of metabolic processes in tissues. We applied these mod-23 els to decipher ammonia detoxification mechanisms in the liver. 24
Methods: An integrated metabolic-spatial-temporal model was 25 used to generate hypotheses of ammonia metabolism. Predicted 26 mechanisms were validated using time-resolved analyses of 27 nitrogen metabolism, activity analyses, immunostaining and 28 gene expression after induction of liver damage in mice. More-29 over, blood from the portal vein, liver vein and mixed venous 30 blood was analyzed in a time dependent manner. 31
Results: Modeling revealed an underestimation of ammonia con-32 sumption after liver damage when only the currently established 33 mechanisms of ammonia detoxification were simulated. By iter-34 ative cycles of modeling and experiments, the reductive amida-35 tion of alpha-ketoglutarate (a-KG) via glutamate dehydrogenase 36
(GDH) was identified as the lacking component. GDH is released 37 from damaged hepatocytes into the blood where it consumes 38 ammonia to generate glutamate, thereby providing systemic pro-39 tection against hyperammonemia. This mechanism was exploited 40 therapeutically in a mouse model of hyperammonemia by 41 injecting GDH together with optimized doses of cofactors. 42
Intravenous injection of GDH (720 U/kg), a-KG ( Recent developments have strongly improved our capability to 56 generate information at multiple spatial and temporal scales 57 [1,2]. However, research on disease pathogenesis is hampered 58 by the difficulty to understand the orchestration of individual 59 components. Here, mathematical models help to formalize rela-60 tions between components, simulate their interplay, and to study 61 processes that are too complex to be understood intuitively [1] . 62 This is particularly important when studying the pathophysiol-63 ogy of metabolic liver diseases, where due to zonation different 64 metabolic processes take place in pericentral and periportal hep-65 atocytes [3] . To be able to investigate such complex processes we 66 recently established a technique of integrated metabolic spatial-67 temporal modeling (IM) [4] . These IM integrate conventional 68 metabolic models into spatial-temporal models of the liver lobule 69 [1,4,5]. The present study was motivated by the IM predictions, 70 which proposed that the conventional mechanisms where 71 ammonia is metabolized by urea cycle enzymes in the periportal 72 compartments of the liver lobules and by glutamine synthetase 73 (GS) reaction in the pericentral compartments ( Supplementary  Fig. 1 ) failed to explain the experimental findings [4] . The IM was 75 applied to an experimental scenario, where the entire pericentral 76 and a part of the periportal compartment of the liver lobules were 77 destroyed by a single high dose of the hepatotoxic compound 78 carbon tetrachloride (CCl 4 ). This leads to compromised nitrogen 79 metabolism and hyperammonemia. In the present study, we per-80 formed a series of new experiments accompanied by simulations 81
with novel models to explore the mechanism responsible for the 82 observed discrepancy. Experimentally, the time-resolved analysis 83 of metabolites and metabolic activities after CCl 4 intoxication 84
offers good conditions to study ammonia detoxification and pos-85 sible compensatory mechanisms during the damage and regener-86 ation process. Time-resolved analysis of metabolites was 87 performed in the portal vein and heart blood, representing the 88 'liver inflow', and in the liver vein as 'liver outflow'. These analy-89
ses allowed a precise experimental validation of model predic-90
tions. Finally, iterative cycles of modeling and experimental 91 validation allowed the identification of a so far unrecognized 92 mechanism of ammonia detoxification. 
124
Statistical analysis was done with SPSS software as described in the Supplemen-125 tary materials.
126 Results
127
An integrated spatial-temporal-metabolic model suggests a so far 128 unrecognized mechanism of ammonia detoxification
129
The detoxification process in healthy, damaged and regenerating 130 livers was simulated using a recently established integrated 131 metabolic IM [4] . To compare the simulated metabolite concen-132 trations with the in vivo situation, an experiment was performed 133 in which blood was collected from the portal vein (representing 134 85% of the 'liver inflow'), the heart (representing 15% of the 'liver 135 inflow'), and the hepatic vein (representing the 'liver outflow') in 136 a time-resolved manner after CCl 4 injection ( Fig. 1A ; Supplemen-137 tary Fig. 2 ). The result shows that ammonia is detoxified during 138 its passage through the liver as illustrated by the difference in 139 ammonia concentrations between the portal vein and the hepatic 140 vein in the control mice ( Fig. 1B) . This detoxification process is 141 compromised after liver damage, particularly on days 1 and 2.
142 Surprisingly, the IM model predicted higher ammonia concentra-143 tions than those experimentally observed, particularly on day 1 144 ( Fig. 1C ; see the video in the Supplementary data). Analyses of 145 heart blood demonstrate the contribution of the extrahepatic 146 compartment, which includes brain, muscles, kidneys and blood, 147 to ammonia detoxification between days 1 and 4 after the induc-148 tion of liver damage. However, this extrahepatic contribution is 149 small compared to detoxification by the liver (Supplementary 150 Figs. 2-8). In addition to the time-resolved study, similar 151 experiments were also performed in a dose dependent manner 152 on day 1 after CCl 4 administration when the discrepancy between 153 simulated and measured ammonia was maximal. For this pur-154 pose, doses ranging between 10.9 and 1600 mg/kg CCl 4 were 155 tested, resulting in a concentration dependent increase in the 156 dead cell area, with only the highest dose causing damage to 157 the entire CYP2E1 positive pericentral region of the liver lobule 158 ( Fig. 1D ; Supplementary Fig. 9A, B ). Destruction of the GS positive 159 area occurred in with doses ranging between 38.1 and 132.4 mg/ 160 kg ( Fig. 1D , E; Supplementary Fig. 9C ); also CPS1 showed a 161 dose dependent decrease ( Supplementary Fig. 9C ) leading to 162 compromised ammonia metabolism ( Supplementary Fig. 10) .
163 Using the IM [4], we also observed a discrepancy between the 164 predicted and measured ammonia in the dose dependent study 165 ( Fig. 1F ).
166 To find an explanation for this discrepancy, we performed 167 time-resolved gene array analysis of mouse liver tissue after 168 CCl 4 intoxication ( Fig. 2A ). Fuzzy clustering identified seven gene 169 clusters which reflected time dependent gene expression alter-170 ations [6] . Clusters 4 and 6 contained genes whose expression 171 was transiently repressed at early time points after CCl 4 intoxica-172 tion ( Fig. 2B ). Further bioinformatics analyses revealed an over 173 representation of nitrogen/ammonia metabolism KEGG and Gene 174 ontology terms of genes in cluster 4 ( Fig. 2C, D) . Genes relevant 175 for ammonia metabolism were further studied by qRT-PCR, 176 immunostaining and activity assays. GS is the key enzyme for 177 ammonia detoxification in the pericentral compartment. RNA 178 levels of GS started to decrease as early as 6 h after CCl 4 injection, 179 it was at its lowest between days 1 and 4, before finally recover-180 ing to initial levels between days 6 and 30 ( Fig. 2E) . A similar 181 time-dependent curve was obtained for GS activity although 182 the decrease occurred slightly later than that of RNA with very 183 low levels between days 2 and 4 ( Fig. 2E ). The pattern and inten-184 sity of GS immunostaining was found to be comparable to GS 185 activity ( Fig. 2F ). In addition, ornithine aminotransferase (OAT), 186 an enzyme exclusively localized in GS positive pericentral hepa-187 tocytes that provides additional glutamate for fixing ammonia 188 [7], decreased to almost undetectable levels with a delayed 189 recovery ( Supplementary Fig. 3A rent increase in glutamate levels, which persisted longer than 209 the drop in a-KG. One potential explanation is the delayed recov-
210
ery of GS, which uses glutamate and ammonia to form glutamine 211 ( Fig. 2E, F) . The decrease in a-KG (and the increase in glutamate)
212
was also accompanied by increased GDH activity in plasma, 213
because GDH is released from damaged hepatocytes (Fig. 3A) .
214
The present observations suggest that GDH released from the 215 damaged hepatocytes into the blood catalyzes, at least tran-216 siently, a reaction that consumes ammonia to produce glutamate 217 ( Fig. 3D ). To test this hypothesis, we collected plasma from mice 218 on day 1 after CCl 4 injection. Addition of a-KG alone was suffi-
219
cient to slightly but significantly decrease blood ammonia con-220 centrations ( Fig. 3B ). This decrease was enhanced by further 221
adding NADPH and particularly GDH; whereas the GDH inhibitor, 222
PDAC completely antagonized the effect. To test also higher 223 ammonia concentrations typically observed in patients with sev-224 ere pre-coma hyperammonemia, 600 lM ammonia was added to 225 plasma collected on day 1 after CCl 4 administration. Under these 226 conditions, a-KG also reduced ammonia and increased glutamate 227 concentrations ( Fig. 3C ; Supplementary Fig. 12A ). Together, these 228 experiments suggest that a GDH reaction consuming ammonia in 229 blood takes place when GDH is released from acutely damaged 230 livers ( Fig. 3D ).
231
Validation of the 'GDH-driven ammonia consumption' in hepatocytes
232
The experiments described above suggest that high ammonia 233
concentrations in plasma leads to a 'reverse' GDH reaction, which 234 consumes rather than produces ammonia. To test whether this 235
'GDH-driven ammonia consumption' occurs not only in plasma 236 but also in cells, we used an in vitro system with primary mouse 237
hepatocytes incubated with ammonia in suspension ( Fig. 4 ).
238
PDAC was used to inhibit GDH ( Fig. 4A ) in order to determine 239 its influence on ammonia metabolism. In hepatocytes isolated 240 from control mice, unphysiologically high ammonia concentra-241 tions (2 mM) were required until PDAC caused a significant 242 increase of ammonia levels in the suspension buffer ( Fig. 4B ). 243
However, when hepatocytes from mice 24 h after CCl 4 intoxica-244 tion were used, PDAC treatment increased ammonia concentra-245 tions in the suspension buffer, even with 0.5 mM ammonia. 246
Furthermore, in the absence of ammonia, hepatocytes secreted 247 a small but statistically significant amount of ammonia into the 248 buffer. Similarly, glutamate production was reduced by PDAC, 249 an effect that was also stronger in hepatocytes isolated from 250 CCl 4 -exposed mice (Fig. 4C) , which corresponds to the reverse 251 GDH reaction proposed in Fig. 3D (right panel). CCl 4 destroys 252 the pericentral hepatocytes ( Fig. 1D) , which explains the reduced 253 glutamine generation by GS ( Fig. 4D ) and compromises urea cycle 254 enzymes ( Supplementary Fig. 3B, C) , which explains the reduced 255 urea production ( Fig. 4E) . Similar experiments were also per-256 formed with cultivated (instead of suspended) hepatocytes from 257 untreated mice. The results demonstrate that inhibition of GDH 258 at high ammonia concentrations increases ammonia-induced 259 cytotoxicity ( Supplementary Fig. 12B ). These results show that 260 the catalytic direction of GDH reverses a clearly becomes ammo-261 nia consuming also in hepatocytes in order to compensate the 262 compromised metabolism by urea cycle enzymes and GS after 263 intoxication.
264 Further evidence emerges from simulations with a set of 265 novel models 1-4 ( Supplementary Fig. 11 ). If a reversible GDH 266 reaction was integrated into the hepatocyte compartment 267 ( Fig. 5A ; Supplementary Fig. 11 ), the discrepancy between 268 in vivo measured and simulated ammonia concentrations 269 (Fig. 1C ) completely disappeared (Fig. 5B ). The quantitative 270 agreement was obtained even without considering the blood 271 compartment of the liver, suggesting that after CCl 4 -induced 272 damage, the ammonia consumption catalyzed by GDH in 273 the hepatocytes represents the missing ammonia sink predicted 274 by [4] .
275
Therapy of hyperammonemia based on the reverse GDH reaction activity. In control mice, injection of a-KG did not alter blood 292 concentrations of ammonia or glutamate (Fig. 6B ). In addition, 293 plasma a-KG levels were lower in CCl 4 -treated mice compared 294 to the control mice, suggesting increased consumption in mice 295 with damaged livers. In the aforementioned experiment, the molar amount of glu-297 tamate produced in the damaged liver after a-KG injection was 298 higher than ammonia consumption (Fig. 6A) . Therefore, the 299 results cannot only be explained by the reverse GDH reaction, 300 but may be due to the consumption of a-KG by transaminases 301 that contribute to the generation of glutamate. Indeed, tail vein 302 injection of the transaminases inhibitor AOA prior to a-KG injec-
303
tion reduced the production of glutamate ( Fig. 6C ) and improved 304 ammonia detoxification. The efficiency of transaminases inhibi-305 tion by AOA in vivo has been confirmed in preliminary experi-306 ments ( Supplementary Figs. 13 and 14) .
307
The reverse GDH reaction requires NADPH as a cofactor; how-308 ever, NADPH concentrations are very low in blood. To determine 309
how NADPH levels are altered in our model of liver damage, both 310 NADPH and its oxidized form NADP + were analyzed. Blood con-311 centrations of both NADPH and NADP + increased after induction 312 of liver damage by CCl 4 (Supplementary Fig. 15A ). In addition, an 313 enhanced NADP + /NADPH ratio was observed in both blood and 314 liver tissue ( Supplementary Fig. 15B ). This increase in NADP + / 315 NADPH ratio fits to a switch in the GDH reaction from NADPH 316 generation to NADPH consumption. Despite the increase in 317 NADPH after induction of liver damage, the concentrations are 318 still relatively low. Therefore, to study the influence of NADPH, 319 plasma from mice collected 24 h after CCl 4 injection was incu-320 bated with varying concentrations of NADPH in the presence of 321 NH 4 Cl (1 mM), a-KG (3 mM), AOA (1 mM) and GDH (12,000 U/ 322 l) for one hour. A concentration dependent decrease in plasma 323 ammonia and an increase in glutamate were observed with 324 increasing concentrations of NADPH ( Fig. 7A) . A similar trend 325 for ammonia and glutamate was observed with increasing con-326 centrations of a-KG and GDH (Fig. 7B, C) . Moreover, addition of 327 AOA reduced both ammonia and glutamate concentrations (Sup-328 plementary Fig. 16 ). To understand how the orientation of the 329 GDH reaction is controlled by ammonia and glutamate concen-330 trations, titration experiments were performed, which indicated 331 that GDH significantly consumes ammonia beginning at concen-332 trations of 150 lM and higher (Fig. 7D) . In contrast, unphysiolog-333 ically high concentrations of more than 10 mM glutamate were 334 required to block the reaction (Fig. 7E) .
335 Based on these in vitro optimized concentrations, we designed 336 an in vivo study to treat hyperammonemia in mice. After the 343 720 U/kg GDH was used because it resulted in plasma levels of 344 approximately 6000 U/l 15 min after injection (Supplementary 345 Fig. 17) , an activity level shown to allow maximal ammonia con-346 sumption in plasma in vitro ( Fig. 7C ). The dose of 180 mg/kg 347 NADPH was also considered as adequate in a pharmacokinetic 348 experiment ( Supplementary Fig. 18 ) as it transiently increased 349 plasma NADPH to approximately 1.6 mM 2 min after injection. 15 min after administration (Fig. 8) . Simultaneously, glutamate 353 levels increased from 131 to 369 lM. Analysis of a-KG and
354
GDH activity in the plasma showed that substitution was suc-355 cessful 15 min after the injection of the KGN cocktail. Moreover, 356
the activities of aspartate and alanine aminotransferase were suc-357
cessfully inhibited by AOA. The mice were observed for three 358 weeks after the experiment and did not show any complications. 
387
Under these conditions, a GDH-catalyzed reaction takes place in 388 blood where ammonia and a-KG are consumed to form gluta-
389
mate in an NADPH-dependent reaction. GDH was also previously 390
reported to switch its catalytic orientation under physiological 391
conditions. In the periportal compartment of the liver lobule, 392
GDH generates ammonia (Fig. 3D) , which fuels the urea cycle. 393
In the pericentral compartment, GDH is known to consume 394 ammonia to generate glutamate for the GS reaction [17] [18] [19] .
395 The present study shows by use of a GDH inhibitor that GDH 396 released from damaged liver tissue may catalyze an ammonia 397 consuming reaction under conditions of hyperammonemia. By 398 releasing GDH from damaged hepatocytes into the blood, the 399 damaged liver provides a mechanism that reduces blood ammo-400 nia levels. However, this protective mechanism is limited by the 
403
age, because it is consumed by the reverse GDH reaction. This 404 prompted us to supplement a-KG, increase blood concentrations 405 of NADPH, and infuse GDH. Indeed, the combined injection of a-
406
KG, GDH and NADPH efficiently reduced blood ammonia concen-407 trations. A GDH bolus was injected to result in plasma peak con-408 centrations between 5000 and 6000 U/L. This is in the same order 409 of magnitude as observed in patients after acetaminophen intox-410
ication [20] . Therefore, in patients with acute liver intoxication 411 with high blood GDH, therapy with a-KG and NADPH might be 412
sufficient. However, it should be considered that the GDH reac-413 tion in blood described here (Fig. 3D) administration when there is no significant increase in blood 416 GDH (Fig. 3A) . This discrepancy may be explained by the intracel-417 lular change of the catalytic direction of GDH in the periportal 418 hepatocytes, which may precede the GDH release into the blood. 419
However, this was not further analyzed in the present study as 420 we choose to focus on the therapeutically more relevant GDH 421 reaction taking place in blood. 422
a-KG was previously tested for the treatment of hyperam-423 monemia between 1964 and 1978 [21, 22] , but this strategy 424 was abandoned because it was not sufficiently efficient for clini-425 cal application. The reverse GDH reaction in the blood and its 426 requirement for NADPH as a cofactor was not yet known when 427 the early therapeutic studies with a-KG were performed. In addi-428 tion, injection of a-KG alone in the present study resulted in only 429 a relatively weak reduction of hyperammonemia. This reduction 430 may be possible because in addition to GDH, NADPH is also 431 released from deteriorating hepatocytes after CCl 4 injection. 432
The concept of treating hyperammonemia by a-KG/GDH/ 433 NADPH infusion originates from simulations using an integrated 434 metabolic spatio-temporal model [4] . This model is based on 435 well-understood pathways of ammonia detoxification, such as 436 urea cycle enzymes and the GS reaction [23, 24] . It predicted 437 higher ammonia concentrations compared to the measured data.
438 Therefore, we analyzed liver tissue during the damage induction 439 and regeneration processes, but the results could also not explain 440 the discrepancy. Time-resolved gene array experiments following 441 CCl 4 injection led to the observation that a general decrease in 442 metabolizing enzymes occurs including enzymes involved in 443 ammonia metabolism. All enzymes of the urea cycle were tran-444 scriptionally downregulated by at least 60%. Factors identified 445 by the gene array analysis were further analyzed by activity 446 assays and immunostaining. Key observations were: (a) the GS 447 positive region, which is initially completely destroyed by CCl 4, 448 shows a delayed recovery and does not return to normal levels 449 before day 12; and (b) CPS1, the rate limiting enzyme in the urea 450 cycle normally expressed in the periportal region, is downregu-451 lated during the destruction process (days 1-3), but its expres-452 sion then extends throughout the entire liver lobule during 453 days 4-6. The other urea cycle enzymes showed a similar time 454 course as CPS1 with the exception of arginase1, which decreased 455 only slightly during the destruction and regeneration process. 456 Glutaminase showed a similar time course and pattern as 457 CPS1. Nevertheless, none of these alterations could explain the 458 observed discrepancy. However, the refined models that take into 459 account the reversible GDH reaction show an excellent agree-460 ment with the experimental data suggesting that consumption 461 by the GDH reaction represents the previously predicted ammo-462 nia sink, hence providing an example for model guided 463 experimentation.
464 In conclusion, a novel form of therapy has been identified that 465 allows the rapid correction of hyperammonemia by the infusion 466 of a-KG, GDH and NADPH. This pharmacotherapy may prove rel-467 evant as an emergency therapy for episodes of hyperammonemia 468 in urea cycle disease or liver cirrhosis.
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